ClinVar Miner

Submissions for variant NM_031885.5(BBS2):c.118G>T (p.Val40Phe)

gnomAD frequency: 0.00002  dbSNP: rs886043059
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000725618 SCV000338210 likely pathogenic not provided 2016-03-18 criteria provided, single submitter clinical testing
Blueprint Genetics RCV001075302 SCV001240919 uncertain significance Retinal dystrophy 2017-12-22 criteria provided, single submitter clinical testing
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego RCV000305383 SCV001443724 likely pathogenic Bardet-Biedl syndrome 2 2019-10-23 criteria provided, single submitter clinical testing This variant has been previously reported as a change in patient with retinal disease (PMID: 28559085). It is absent from the ExAC and gnomAD population databases and thus is presumed to be rare. The c.118G>T (p.Val40Phe) variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.118G>T (p.Val40Phe) variant is classified as Likely Pathogenic.
Myriad Genetics, Inc. RCV000305383 SCV002060203 uncertain significance Bardet-Biedl syndrome 2 2021-11-03 criteria provided, single submitter clinical testing NM_031885.3(BBS2):c.118G>T(V40F) is a missense variant classified as a variant of uncertain significance in the context of Bardet-Biedl syndrome, BBS2-related. V40F has been observed in cases with relevant disease (PMID: 28559085). Functional assessments of this variant are not available in the literature. V40F has not been observed in population frequency databases. In summary, there is insufficient evidence to classify NM_031885.3(BBS2):c.118G>T(V40F) as pathogenic or benign. Please note: this variant was assessed in the context of healthy population screening.
3billion RCV002250616 SCV002521059 uncertain significance Retinitis pigmentosa 74 2022-05-22 criteria provided, single submitter clinical testing The variant is not observed in the gnomAD v2.1.1 dataset. Protein truncation variants are a common disease-causing mechanism. In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.88; 3Cnet: 3CNET). Same nucleotide change resulting in same amino acid change has been previously reported to be associated with BBS2 related disorder (ClinVar ID: VCV000285263 / PMID: 28559085). However, the evidence of pathogenicity is insufficient at this time. Therefore, this variant is classified as uncertain significanceaccording to the recommendation of ACMG/AMP guideline.
Invitae RCV002519177 SCV003443338 uncertain significance Bardet-Biedl syndrome 2022-08-05 criteria provided, single submitter clinical testing This sequence change replaces valine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 40 of the BBS2 protein (p.Val40Phe). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Bardet-Biedl syndrome (PMID: 28559085). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 285263). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Baylor Genetics RCV000305383 SCV004214003 likely pathogenic Bardet-Biedl syndrome 2 2023-09-19 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.